Our lab has contributed to an understanding of cancer biology in two areas. The first involves transcription factors that promote or suppress the oncogenic Epithelial-Mesenchymal Transition (EMT). EMT is a gene expression program that confers tumor cell invasion, metastasis, drug-resistance and cancer stemness. Currently, we are focusing on a newly discovered factor that ubiquitously reverses EMT. The second area stems from our discovery that normal epithelial cells –but not tumor cells that have undergone EMT – die via apoptosis when detached from their extracellular matrix. This process, called “anoikis”, safeguards against tumor metastasis. We are currently investigating intracellular metabolic changes accompanying EMT that impact upon anoikis. A recent, major focus area in the Frisch lab is the control of epigenetic marks, especially histone modifications, during EMT, and how these impact upon drug resistance and tumor recurrence. We are also interested in how the tumor cell differentiation state affects the ability of various immune cells to target the tumor, especially with regard to interferon responses. Our projects are highly translational, with discoveries informing the development of novel drugs to suppress metastasis and tumor recurrence in patients.